ライフサイエンスコーパス: psychotic depression

1 ay be a risk factor for later development of psychotic depression.

2 psychotic bipolar disorder, and 22 days for psychotic depression.

3 er rate of cortisol nonsuppression occurs in psychotic depression.

4 te was substantially higher in patients with psychotic depression (64%) than in nonpsychotic patients

5 nts aged 18 years or older had an episode of psychotic depression acutely treated with sertraline plu

6 of an association between panic symptoms and psychotic depression among female patients and between b

7 rs and annually thereafter; 98 of those with psychotic depression and 434 of those with non-psychotic

8 ral brain networks in patients with remitted psychotic depression and brain-behavior relationships we

9 Hypercortisolemia is usually present in psychotic depression and may be important in understandi

10 ces in performance between the patients with psychotic depression and those with nonpsychotic depress

11 ovide additional support for the validity of psychotic depression as a diagnostic category distinct f

12 Of these, 144 (18.3%) had psychotic depression as defined here.

13 A positive DST result was associated with psychotic depression but was not related to vital status

14 Participants with bipolar disorder, psychotic depression, dementia, or neurological disease

15 Patients with psychotic depression had a pattern of neuropsychological

16 Those who began follow-up with psychotic depression had fewer weeks with minimal sympto

17 Patients with psychotic depression have a two-fold greater risk of dea

18 elatively few studies on the neurobiology of psychotic depression have been pursued.

19 Neuroimaging studies investigating psychotic depression have provided evidence for distribu

20 antly higher mortality rate in patients with psychotic depression (hazards ratio=2.31).

21 ticipated in the Study of Pharmacotherapy of Psychotic Depression II randomized controlled trial.

22 ata from the Study of the Pharmacotherapy of Psychotic Depression II trial (STOP-PD II), a randomized

23 ating in the Study of the Pharmacotherapy of Psychotic Depression II.

24 Among patients with psychotic depression in remission, continuing sertraline

25 g antipsychotic medication for patients with psychotic depression in remission.

26 Psychotic depression is a severely disabling and potenti

27 Among patients with major depression, psychotic depression is the subtype that is most closely

28 depressive disorder with psychotic features (psychotic depression) is a severe disorder.

29 he index episode and the first recurrence of psychotic depression lasted longer than nonpsychotic epi

30 s-sectional sample of patients with remitted psychotic depression (n = 86) collected to date.

31 were collected at the time of recurrence of psychotic depression or sustained remission.

32 Psychotic depression (PD) is a severe mental disorder le

33 20 weeks, only two (4%) of the patients with psychotic depression received at least one adequate phar

34 Twenty-five (47%) of the patients with psychotic depression received either no neuroleptic trea

35 sychiatric profile of patients with unipolar psychotic depression, relative to that of patients with

36 ological impairment associated with unipolar psychotic depression remains unclear.

37 neurologic condition, studies of bipolar or psychotic depression, studies that included children or

38 psychological profiles for schizophrenia and psychotic depression suggest that these psychotic disord

39 of cortisol has frequently been reported in psychotic depression, the findings have been mixed.

40 We compared patients with remitted psychotic depression to healthy controls and found that

41 ychological characteristics of patients with psychotic depression to those of patients with nonpsycho

42 The mortality rate for subjects with psychotic depression was significantly greater than that

43 The patients with psychotic depression were comparable to those with schiz

44 study arm, and participants with bipolar or psychotic depression were excluded.

45 ychotic depression and 434 of those with non-psychotic depression were followed for 10 years.

46 d, placebo-controlled trial in patients with psychotic depression who attained remission on sertralin

47 The authors hypothesized that patients with psychotic depression would have higher mortality rates t

48 tion of hospitalized patients and those with psychotic depression would help to determine whether the